These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33007508)

  • 21. Mitochondrial Lipid Homeostasis at the Crossroads of Liver and Heart Diseases.
    Dabravolski SA; Bezsonov EE; Baig MS; Popkova TV; Orekhov AN
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203309
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of diabetes on subclinical atherosclerosis and major cardiovascular events in individuals with and without non-alcoholic fatty liver disease.
    Wang B; Zhao Z; Liu S; Wang S; Chen Y; Xu Y; Xu M; Wang W; Ning G; Li M; Wang T; Bi Y
    Diabetes Res Clin Pract; 2021 Jul; 177():108873. PubMed ID: 34051282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases.
    Cai J; Zhang XJ; Ji YX; Zhang P; She ZG; Li H
    Circ Res; 2020 Feb; 126(5):679-704. PubMed ID: 32105577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
    Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk.
    Alkhouri N; Tamimi TA; Yerian L; Lopez R; Zein NN; Feldstein AE
    Dig Dis Sci; 2010 Sep; 55(9):2644-50. PubMed ID: 19960252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease.
    Duran EK; Aday AW; Cook NR; Buring JE; Ridker PM; Pradhan AD
    J Am Coll Cardiol; 2020 May; 75(17):2122-2135. PubMed ID: 32354380
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease.
    Tucker B; McClelland RL; Allison MA; Budoff MJ; Wu BJ; Barter PJ; Rye KA; Ong KL
    Atherosclerosis; 2020 Apr; 299():38-44. PubMed ID: 32220662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease.
    Luo J; Xu L; Li J; Zhao S
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):193-9. PubMed ID: 25563143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.
    Cohen DE; Fisher EA
    Semin Liver Dis; 2013 Nov; 33(4):380-8. PubMed ID: 24222095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease.
    Arvind A; Henson JB; Osganian SA; Nath C; Steinhagen LM; Memel ZN; Donovan A; Balogun O; Chung RT; Simon TG; Corey KE
    Hepatol Commun; 2022 Feb; 6(2):309-319. PubMed ID: 34558862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atherosclerosis and Associated Cardiovascular Risk Factors in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome.
    Bajaj S; Prajapati SK
    J Assoc Physicians India; 2022 Jun; 70(6):11-12. PubMed ID: 35702845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early Predictors of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease: Non-obese Versus Obese Patients.
    Shao C; Ye J; Li F; Lin Y; Wu T; Wang W; Feng S; Zhong B
    Dig Dis Sci; 2020 Jun; 65(6):1850-1860. PubMed ID: 31724099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications.
    Byrne CD; Targher G
    Diabetes Obes Metab; 2022 Feb; 24 Suppl 2():28-43. PubMed ID: 34324263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of serum atherogenic risk in liver transplant recipients: Role of lipoproteins and metabolic and inflammatory markers.
    Chhatrala R; Siddiqui MB; Stravitz RT; Driscoll C; Sanyal A; Sargeant C; Luketic V; Sharma A; Sterling R; Matherly S; Puri P; Siddiqui MS
    Liver Transpl; 2015 May; 21(5):623-30. PubMed ID: 25762084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dyslipidemia in patients with nonalcoholic fatty liver disease.
    Chatrath H; Vuppalanchi R; Chalasani N
    Semin Liver Dis; 2012 Feb; 32(1):22-9. PubMed ID: 22418885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonalcoholic fatty liver disease and cardiovascular disease.
    Hyogo H; Chayama K; Yamagishi S
    Curr Pharm Des; 2014; 20(14):2403-11. PubMed ID: 23844815
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor.
    Konishi K; Miyake T; Furukawa S; Senba H; Kanzaki S; Nakaguchi H; Yukimoto A; Nakamura Y; Watanabe T; Koizumi Y; Yoshida O; Tokumoto Y; Hirooka M; Kumagi T; Abe M; Matsuura B; Hiasa Y
    Atherosclerosis; 2020 Apr; 299():32-37. PubMed ID: 32203743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonalcoholic Fatty Liver Disease as an Emerging Risk Factor and Potential Intervention Target for Atherosclerotic Cardiovascular Diseases.
    Zhang D; Mi Z; Peng J; Yang T; Han Y; Zhai Y; Song C; Teng X; Sun W; Guo J; Bilonda KP
    J Cardiovasc Pharmacol; 2023 May; 81(5):327-335. PubMed ID: 36917556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The association of the steatosis severity, NAFLD fibrosis score and FIB-4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross-sectional study.
    Tutunchi H; Naeini F; Ebrahimi-Mameghani M; Mobasseri M; Naghshi S; Ostadrahimi A
    Int J Clin Pract; 2021 Jun; 75(6):e14131. PubMed ID: 33683797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.